Possibilities for diagnosing essential thrombocythemia at the stage of primary health care

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This clinical case presents a 39-year-old woman diagnosed with essential thrombocythemia, accompanied by a review of the epidemiology, clinical and diagnostic criteria, and patient management strategies. The case also includes a discussion of potential complications and prognosis associated with the condition. The importance of thorough outpatient monitoring is emphasized, which should include regular assessments of clinical symptoms, changes in blood count parameters, bone marrow trephine biopsy, and molecular genetic testing for MPL and CALR gene mutations. The report highlights gaps in the current medical examination process, suggesting that addressing these deficiencies could improve early detection of essential thrombocythemia and enable timely pathogenetic therapy with antiplatelet agents to prevent complications.

Full Text

Restricted Access

About the authors

Vitaly V. Gorban

Kuban State Medical University

Email: gorbanvv@mail.ru
ORCID iD: 0000-0001-8665-6796

MD, Dr. Sci. (Medicicne)

Russian Federation, Krasnodar

Valeria S. Manto

Kuban State Medical University

Author for correspondence.
Email: lera.menshikh@mail.ru
ORCID iD: 0000-0001-5601-6034

Postgraduate Student

Russian Federation, Krasnodar

Nikita O. Bergen

Kuban State Medical University

Email: Fredibergsn23@mail.ru
ORCID iD: 0009-0000-0676-0367
Russian Federation, Krasnodar

Kamilla A. Arzumanyan

Kuban State Medical University

Email: arzumanyan.kamilla@mail.ru
ORCID iD: 0000-0001-8739-6340
Russian Federation, Krasnodar

References

  1. Yu Y, Zhang X, Shi Q, et al. Essential thrombocytosis with recurrent spontaneous abortion in the mid trimester: a case report. Medicine (Baltimore). 2019;98(26):e16203. doi: 10.1097/MD.0000000000016203
  2. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–679. doi: 10.1182/blood-2016-10-695940
  3. Melikjan AL, Subortseva IN, Sudarikov AB, et al. Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease. Therapeutic Archive. 2017;89(7):4–9. EDN: ZBMLSH doi: 10.17116/terarkh20178974-9
  4. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354. doi: 10.1002/jca.21705
  5. Melikyan AL, Kovrigina AM, Subortseva IN, et al. National сlinical recommendations for diagnosis and therapy of ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018). Russian journal of hematology and transfusiology. 2018;63(3):275–315. EDN: ZCZBHN doi: 10.25837/HAT.2019.51.88.001
  6. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–1613. doi: 10.1002/ajh.26008
  7. Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Exp Rev Hematol. 2019;12(3):159–171. doi: 10.1080/17474086.2019.1585239
  8. Accurso V, Santoro M, Mancuso S, et al. The essential thrombocythemia in 2020: What we know and where we still have to dig deep. Clin Med Insights Blood Disord. 2020;13:2634853520978210. doi: 10.1177/2634853520978210
  9. İskender D, Yılmaz-Ergani S, Aksoy M, et al. High rate of obstetric complications in patients with essential thrombocythemia. Cureus. 2021;13(12):e20449. doi: 10.7759/cureus.20449
  10. Kwiatkowski J, Kuliszkiewicz-Janus M, Potoczek S, et al. What factors determine the pregnancy outcome in patients with essential thrombocythemia? J Matern Fetal Neonatal Med. 2022;35(24):4734–4738. doi: 10.1080/14767058.2020.1863362
  11. Cattaneo D, Croci GA, Bucelli C, et al. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. a single-center cohort study. Front Oncol. 2021;12(11):637116. doi: 10.3389/fonc.2021.637116
  12. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. doi: 10.1182/blood-2014-05-579136
  13. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544
  14. Wang Y, Ran F, Lin J, et al. Genetic and clinical characteristics of patients with philadelphia-negative myeloproliferative neoplasm carrying concurrent mutations in JAK2V617F, CALR, and MPL. Technol Cancer Res Treat. 2023;22:15330338231154092. doi: 10.1177/15330338231154092
  15. Mroczkowska-Bękarciak A, Wróbel T. BCR: ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing. Front Genet. 2023;14:1241912. doi: 10.3389/fgene.2023.1241912
  16. Okazaki H, Doi T, Izumikawa M, et al. Pulsatile tinnitus as a first symptom of essential thrombocythemia. Am J Otolaryngol. 2011;32(3):263–264. doi: 10.1016/j.amjoto.2010.03.004
  17. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528–544. doi: 10.1080/09537100600758677
  18. Inoue S, Okiyama N, Okune M, et al. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works. J Dermatol. 2017;44(1):84–87. doi: 10.1111/1346-8138.13561
  19. Robinson AJ, Godfrey AL. Low-risk essential thrombocythemia: a comprehensive review. Hemasphere. 2021;5(2):e521. doi: 10.1097/HS9.0000000000000521
  20. Zulkeflee RH, Zulkafli Z, Johan MF, et al. Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in malaysian patients with classical myeloproliferative neoplasm (MPN). Int J Environ Res Public Health. 2021;18(14):7582. doi: 10.3390/ijerph18147582
  21. Gaman AM, Moisa C, Diaconu CC, Gamanet MA. Crosstalk between oxidative stress, chronic inflammation and disease progression in essential thrombocythemia. Rev Chim. 2019;70(10):3486–3489. doi: 10.37358/RC.19.10.7581
  22. Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729–1737. doi: 10.1182/bloodadvances.2019000211
  23. Awada H, Voso MT, Guglielmelli P, et al. Essential thrombocythemia and acquired von willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers (Basel). 2020;12(7):1746. doi: 10.3390/cancers12071746
  24. Abu-Tineh M, Yassin MA. Extreme levels of platelet count in essential thrombocythemia: management and outcome, report of two cases. Case Rep Oncol. 2020;13(2):606–610. doi: 10.1159/000507363
  25. Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia. Blood. 2011;117(5):1472–1482. doi: 10.1182/blood-2010-08-270033
  26. Sakamoto Y, Nito C, Abe A, et al. Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: a case report. J Neurol Sci. 2016;15(365):74–75. doi: 10.1016/j.jns.2016.04.014

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.